Biotech


  • A photograph of Upstream Bio CEO Samantha Truex
    Image attribution tooltip
    Permission granted by Upstream Bio
    Q&A

    Samantha Truex on biotech hiring, competing for funding and Upstream’s next steps

    The CEO recently led Upstream through a $200 million financing that will support development of an inflammatory disease drug. “We have what investors probably want at this time,” she told BioPharma Dive.

    By Aug. 9, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Karuna shares soar on schizophrenia drug results

    The company plans to ask regulators to approve its KarXT therapy based on the results, which one analyst called “as good as one could hope for.”

    By Aug. 8, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    Acadia turned back by FDA on second attempt to get psychosis drug approved

    The agency issued Acadia a complete response letter for pimavanserin, for which the company had sought to win an expanded clearance in Alzheimer’s disease psychosis.

    By Aug. 5, 2022
  • Boston Children's Hospital doctor and laboratory director George Daley
    Image attribution tooltip
    Permission granted by Michael Goderre / Boston Children’s Hospital
    Emerging biotech

    ElevateBio, Boston Children’s launch startup to test new approach to ‘off-the-shelf’ cell therapy

    Spun out of a Boston Children’s research lab, the biotech is the first to emerge from a partnership ElevateBio and the hospital struck to create new cell and gene therapy companies.

    By Aug. 4, 2022
  • An employee handles product in Gilead's cell therapy unit.
    Image attribution tooltip
    Gilead Sciences Inc.

    Gilead, following cell therapy approval, impresses Wall Street with fast sales

    Together, the biotech’s two CAR-T therapies earned $368 million between April and June, a substantial jump over last year and above what analysts forecast.

    By Aug. 3, 2022
  • Red human heart drawing on blue background
    Image attribution tooltip
    Jolygon via Getty Images

    Alnylam drug succeeds in key heart disease study, boosting company

    The success of Alnylam's treatment in a trial known as APOLLO-B could pave the way for the biotech to reach consistent profitability, should the FDA sign off on a planned approval application.

    By Aug. 3, 2022
  • Alexis Borisy
    Image attribution tooltip
    Courtesy of IDRx

    IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations

    Founded by entrepreneur Alexis Borisy, the company comes equipped with two experimental medicines it licensed from Merck KGaA and Blueprint Medicines.

    By Aug. 2, 2022
  • Strand Therapeutics CEO Jake Becraft
    Image attribution tooltip
    Courtesy of Strand Therapeutics
    Q&A // Emerging biotech

    Strand CEO on founder-led biotech, venture capital and the market’s retreat

    Jake Becraft, founder and current chief of mRNA startup Strand Therapeutics, argues biotech would be healthier if more scientists and researchers lead the companies they start.

    By Aug. 2, 2022
  • Leaders of Belite Bio posing in front of Belite Bio Nasdaq stock market listing
    Image attribution tooltip

    Photography courtesy of Nasdaq, Inc.

    Emerging biotech

    How Belite Bio, a small, under-the-radar drugmaker, emerged as one of biotech’s best performing IPOs

    Belite's shares have risen nearly 500% from their IPO price at a time when many other newly public biotech companies are struggling to hold their value.

    By Updated Aug. 2, 2022
  • Image attribution tooltip
    Getty Images

    Nuvation to cut workforce by 35% as it scraps lead drug program

    The company, which is led by former Medivation executives and focuses on cancer research, said the shake-up is in response to an “internal risk-benefit analysis” that raised doubts about its most advanced program.

    By Aug. 1, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    Concert to seek approval for hair loss drug after second study success

    The biotech plans to file an application with the FDA in the first half of next year for clearance in alopecia areata, potentially positioning it to compete with Eli Lilly and Pfizer for market share.

    By Aug. 1, 2022
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta

    Sarepta to ask FDA for accelerated approval of Duchenne gene therapy

    After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.

    By July 29, 2022
  • Image attribution tooltip
    Alnylam Pharmaceuticals

    Alnylam reveals longer wait for anticipated drug trial results

    Important data from the APOLLO study of the biotech's drug Onpattro are due before the end of August, Alnylam said Thursday.

    By July 28, 2022
  • Vicinitas Therapeutics founder Daniel Nomura
    Image attribution tooltip
    Courtesy of Vicinitas Therapeutics
    Emerging biotech

    Novartis-linked startup launches with technology designed to remove ‘destroy’ tags on helpful proteins

    Vicinitas and its protein-stabilizing research have attracted $65 million from a group of investors that includes a16z, Deerfield and GV.

    By July 28, 2022
  • An AbCellera scientist preparing reagents for a molecular biology assay
    Image attribution tooltip
    Courtesy of AbCellera
    Emerging biotech

    Versant partners with AbCellera to arm startups with better antibodies

    The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO. 

    By July 27, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    BridgeBio advances drug for dwarfism after study data

    The highest tested dose of BridgeBio’s drug helped the bones of children with achondroplasia grow faster, leading the company to expand study enrollment.

    By July 26, 2022
  • A photo of a Seattle Genetics laboratory
    Image attribution tooltip
    Permission granted by Seagen

    Seagen, Astellas claim positive results in study key to cancer drug's success

    The mid-stage trial tested the companies’ drug Padcev with Merck’s Keytruda in first-line bladder cancer. The data are reportedly a factor in Merck’s talks with Seagen over a potential buyout.

    By July 26, 2022
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    ALS drug development

    FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug

    Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators.

    By July 26, 2022
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    libre de droit via Getty Images
    Emerging biotech

    Epigenetic editing: a tunable CRISPR alternative

    Three startups have recently emerged with plans to edit the epigenome rather than DNA directly. Here’s why that matters and what they aim to do. 

    By July 26, 2022
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Deep Dive // Emerging biotech

    'Flat is the new up': After biotech correction, venture investors turn to safer bets

    New companies are being built more carefully and platform technologies are less in vouge as the downturn's effects ripple through the private sector.

    By July 26, 2022
  • Single strand ribonucleic acid, RNA research
    Image attribution tooltip
    luismmolina via Getty Images

    China-based biotech licenses Sanofi's RNA drug technology

    The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.

    By Updated July 25, 2022
  • A rendering of Astellas' planned biotech campus in South San Francisco
    Image attribution tooltip
    Courtesy of Astellas

    Astellas to bring research units under one roof in new West Coast center

    The pharma company plans to spend $70 million on the South San Francisco facility, which will house West Coast employees of Astellas Gene Therapies.

    By July 22, 2022
  • Calculator
    Image attribution tooltip
    "Calculator" by stevepb is licensed under CC BY-SA 2.0

    Assembly Bio scraps hepatitis B drug, cuts staff after clinical setback

    Two top executives will depart in a restructuring that will reduce the California biotech’s staff by 30% and prioritize a pair of preclinical research programs.  

    By Kristin Jensen • July 21, 2022
  • Sekar Kathiresan and the Verve team ring the Nasdaq closing bell for their company's IPO in June.
    Image attribution tooltip
    Permission granted by Sekar Kathiresan

    Vertex, Verve team up to develop a gene editing drug for liver disease

    The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.

    By July 20, 2022
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen

    With Aduhelm sidelined, Wall Street turns to Biogen's next Alzheimer's drug

    On the company’s latest earnings call, analysts pressed for more details about the drug, called lecanemab, including its odds for approval and how that could reshape Biogen.

    By July 20, 2022